{"id":48862,"date":"2025-11-24T20:07:39","date_gmt":"2025-11-24T12:07:39","guid":{"rendered":"https:\/\/flcube.com\/?p=48862"},"modified":"2025-11-24T20:07:40","modified_gmt":"2025-11-24T12:07:40","slug":"cspcs-syh2056-wins-nmpa-nod-for-depression-trials-as-fast%e2%80%91acting-5%e2%80%91ht2a-agonist","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48862","title":{"rendered":"CSPC&#8217;s SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that <strong>SYH2056<\/strong>, a <strong>selective 5\u2011HT2A receptor agonist<\/strong>, received <strong>clinical trial approval<\/strong> from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>depression<\/strong>, offering a potential fast\u2011acting, single\u2011dose therapy without hallucination risk.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>SYH2056<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group (1093.HK)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Depressive disorders<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Selective 5\u2011HT2A receptor agonist<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Initiate Phase\u202fI dose\u2011finding study Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Activates <strong>5\u2011HT2A receptors<\/strong> to rapidly improve depressive symptoms<\/li>\n\n\n\n<li><strong>Key Features:<\/strong><\/li>\n\n\n\n<li><strong>Fast\u2011acting<\/strong> with single\u2011dose administration<\/li>\n\n\n\n<li><strong>Long\u2011lasting therapeutic effect<\/strong><\/li>\n\n\n\n<li><strong>No hallucination risk<\/strong> (unlike non\u2011selective psychedelics)<\/li>\n\n\n\n<li><strong>Preclinical Data:<\/strong> Promotes <strong>dendrite and dendritic spine formation<\/strong> in central neurons, indicating <strong>neuronal remodeling<\/strong> potential<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Addresses unmet need for rapid\u2011onset antidepressants without psychotomimetic side effects<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Depression Patients<\/strong><\/td><td><strong>~95\u202fmillion<\/strong> (2024)<\/td><\/tr><tr><td><strong>Treatment\u2011Resistant Depression<\/strong><\/td><td>~30% of diagnosed patients<\/td><\/tr><tr><td><strong>Antidepressant Market Size<\/strong><\/td><td>\u00a542\u202fbillion (US$5.8\u202fbillion)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>9% (2024\u20112030)<\/td><\/tr><tr><td><strong>Peak Sales Forecast (SYH2056)<\/strong><\/td><td><strong>\u00a52.5\u20113.5\u202fbillion<\/strong> (US$340\u2011480\u202fmillion) by 2032<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>5\u20118% of treatment\u2011resistant segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong> Dominated by <strong>SSRIs\/SNRIs<\/strong> (e.g., Pfizer\u2019s Zoloft, Eli Lilly\u2019s Cymbalta); rapid\u2011acting options limited to <strong>esketamine nasal spray<\/strong> (Johnson &amp; Johnson) and <strong>agomelatine<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Advantage:<\/strong> NMPA\u2019s acceptance of novel mechanism may qualify SYH2056 for <strong>Breakthrough Therapy Designation<\/strong> after Phase\u202fII data<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Mechanism aligns with FDA\u2019s interest in rapid\u2011acting antidepressants; U.S. IND filing possible <strong>H2\u202f2027<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding SYH2056\u2019s clinical development, regulatory pathway, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, safety profiles, and competitive dynamics in the antidepressant market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112101396_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025112101396_c.\"><\/object><a id=\"wp-block-file--media-1aaf6d28-ca8a-4d02-b105-28de12d56200\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112101396_c.pdf\">2025112101396_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112101396_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1aaf6d28-ca8a-4d02-b105-28de12d56200\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5\u2011HT2A receptor agonist, received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48864,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[171,855],"class_list":["post-48862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC&#039;s SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5\u2011HT2A receptor agonist, received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of depression, offering a potential fast\u2011acting, single\u2011dose therapy without hallucination risk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48862\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC&#039;s SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5\u2011HT2A receptor agonist, received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of depression, offering a potential fast\u2011acting, single\u2011dose therapy without hallucination risk.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48862\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T12:07:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T12:07:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2403.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC&#8217;s SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist\",\"datePublished\":\"2025-11-24T12:07:39+00:00\",\"dateModified\":\"2025-11-24T12:07:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2403.webp\",\"keywords\":[\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48862#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48862\",\"name\":\"CSPC's SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2403.webp\",\"datePublished\":\"2025-11-24T12:07:39+00:00\",\"dateModified\":\"2025-11-24T12:07:40+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5\u2011HT2A receptor agonist, received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of depression, offering a potential fast\u2011acting, single\u2011dose therapy without hallucination risk.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48862\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2403.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2403.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC's SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48862#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC&#8217;s SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC's SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5\u2011HT2A receptor agonist, received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of depression, offering a potential fast\u2011acting, single\u2011dose therapy without hallucination risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48862","og_locale":"en_US","og_type":"article","og_title":"CSPC's SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5\u2011HT2A receptor agonist, received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of depression, offering a potential fast\u2011acting, single\u2011dose therapy without hallucination risk.","og_url":"https:\/\/flcube.com\/?p=48862","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-24T12:07:39+00:00","article_modified_time":"2025-11-24T12:07:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2403.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48862#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48862"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC&#8217;s SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist","datePublished":"2025-11-24T12:07:39+00:00","dateModified":"2025-11-24T12:07:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48862"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48862#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2403.webp","keywords":["CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48862#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48862","url":"https:\/\/flcube.com\/?p=48862","name":"CSPC's SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48862#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48862#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2403.webp","datePublished":"2025-11-24T12:07:39+00:00","dateModified":"2025-11-24T12:07:40+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5\u2011HT2A receptor agonist, received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of depression, offering a potential fast\u2011acting, single\u2011dose therapy without hallucination risk.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48862#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48862"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48862#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2403.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2403.webp","width":1080,"height":608,"caption":"CSPC's SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48862#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC&#8217;s SYH2056 Wins NMPA Nod for Depression Trials as Fast\u2011Acting 5\u2011HT2A Agonist"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2403.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48862"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48862\/revisions"}],"predecessor-version":[{"id":48865,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48862\/revisions\/48865"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48864"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}